Sickle Cell Disease
Pipeline by Development Stage
Drug Modality Breakdown
On Market (3)
Approved therapies currently available
Competitive Landscape
27 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 6,275 patients across 50 trials
Voxelotor Brain Oxygenation and Neurocognitive Study
Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Open-Label Extension Study to Pioneer Study 6058-SCD-101
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
A Study of IMR-687 in Subjects With Sickle Cell Disease
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
Pain Management in Children and Young Adults With Sickle Cell Disease
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Omega-3 Fatty Acids in Sickle Cell Disease
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
A GBT021601 ADME Microtracer Study in Healthy Volunteers
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease
Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
A Study of IMR-687 in Healthy Adult Volunteers
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease